Full Text of PDF (370k)
Article in Japanese
Abstract
Case Report
Successful dose reduction therapy with crizotinib for ROS1-positive lung cancer
Haruka Takahashia,b Tatsuru Ishikawab Yosuke Shionoyab Midori Hashimotob Hiromitsu Doumenc Kaoru Nishiyamab
aDepartment of Respiratory Medicine, JR Sapporo Hospital
bDepartment of Respiratory Medicine, NTT-East Sapporo Hospital
cDepartment of Thoracic Surgery, NTT-East Sapporo Hospital
ABSTRACT
A 65-year-old man with postoperative recurrent ROS1-positive lung cancer was started on crizotinib 250 mg twice a day. However, fever, rash, and liver dysfunction (Grade 3) were observed resulting in discontinuation of crizotinib. The patient was treated with prednisolone which resulted in rapid improvement. After recovery from the adverse effects, we started on crizotinib 50 mg daily. Crizotinib was increased by 50 mg every 7 days, but it was discontinued because of liver dysfunction. Next, dose reduction therapy with crizotinib was selected. It resulted in a good response for 13 months without apparent adverse effects. Dose reduction therapy could be an effective treatment for patients with serious adverse effects.
KEYWORDS
Crizotinib ROS proto-oncogene 1 Dose reduction therapy
Received 29 Jul 2022 ／ Accepted 11 Oct 2022
AJRS, 12(1): 50-53, 2023
Copyright © The Japanese Respiratory Society All Rights Reserved.